Prognostic impact of cyclin-dependent kinase inhibitor p27(kip1) in node-positive breast cancer

Journal of Surgical Oncology

Volumn 70, Issue 4, 1999, Pages 230-234

  Tsuchiya, Atsuo ^a   Zhang, Guo Jun ^a   Kanno, Masahiko ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; p27; Prognostic factor; Survival

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; ESTROGEN RECEPTOR; PROTEIN P27;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MENOPAUSE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 0345369680     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199904)70:4<230::AID-JSO6>3.0.CO;2-I     Document Type: Article

References (17)

1. kip1) of cyclin-dependent kinase 4 activation. Cell 1994;79:487-496.
2. Fisher B, Redmond C, Fisher ER, et al.: The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology - An overview of findings. Cancer 1980;46:1009-1025.
3. Clark GM: Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 1996;30:117-126.
4. 1a,b) invasive breast carcinomas. Cancer Res 1997;57:1259-1263.
5. kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1997;3:222-225.
6. kip1 protein: Prognostic implications in primary breast cancer. Nature Med 1997;3:227-230.
7. Loda M, Cukor B, Tam SW, et al.: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997;3:231-234.
8. kip1 is associated with advanced stage and invasiveness of gastric carcinoma. Jpn J Cancer Res 1997;88:625-629.
9. McGuire WL, DeLaGarza M: Improved sensitivity in the measurement of estrogen receptor in human breast cancer. J Clin Endocrinol Metab 1973;37:986-989.
10. Kawamata N, Morosetti R, Miller CW, et al.: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/kip1 in human malignancies. Cancer Res 1995;55:2266-2269.
11. Spirin KS, Simpson JF, Takeuchi S, et al.: p27/kip1 mutation found in breast cancer. Cancer Res 1996;56:2400-2404.
12. kip1. J Clin Invest 1996;97:1983-1988.
13. kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380-6385.
14. kip1 expression in endocrine and other tumors. Am J Pathol 1997;150:401-407.
15. kip1 accumulation during the cell cycle. Science 1996;271:1861-1864.
16. Pagano M, Tam SW, Theodoras AM, et al.: Role of the ubiquitin-proteasome pathway in regulation abundance of the cyclin-dependent kinase inhibitor p27. Science 1996;269:682-685.
17. kip1 on resistance of tumor cells to anticancer agents. Nature Med 1996;2:1204-1210.